Other languages Immuron Limited Nasdaq

Equities

Market Closed - Nasdaq Other stock markets 21:30:00 25/06/2024 BST			5-day change	1st Jan Change
2.5 ^USD	0.00%		+17.92%	+33.33%

06-05	Immuron Limited Appoints Jeannette Joughin as Director	CI
05-31	Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	CI

Immuron Limited Appoints Jeannette Joughin as Director	06-05
Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	05-31
Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	05-02
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	04-10
Sector Update: Health Care Stocks Gain Late Afternoon	03-07
Sector Update: Health Care	03-07
Top Midday Gainers	03-07
Top Premarket Gainers	03-07
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	03-07
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	03-07
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28
Immuron Posts Record Travelan Sales in Fiscal H1	01-16
Immuron Limited Clinical Trials Update	12-22
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	12-04
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	18/10/23
Immuron Reports Big Jump in Fiscal Q1 Travelan Sales	11/10/23
Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23
Immuron Limited Receives TGA GMP Clearance	09/08/23
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%	09/08/23
Immuron Says First Patients Enrolled in Travelan Trial	25/07/23

No results for this search